Next Article in Journal
Perception about Health Applications (Apps) in Smartphones towards Telemedicine during COVID-19: A Cross-Sectional Study
Next Article in Special Issue
Postoperative Inpatient Rehabilitation Does Not Increase Knee Function after Primary Total Knee Arthroplasty
Previous Article in Journal
Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
Previous Article in Special Issue
Multiple Sclerosis and Autoimmune Comorbidities
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Pan-Cancer Atlas of Differentially Interacting Hallmarks of Cancer Proteins

1
Department of Bioengineering, Marmara University, Istanbul 34854, Turkey
2
Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, Istanbul 34854, Turkey
3
Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, PA 17033, USA
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
J. Pers. Med. 2022, 12(11), 1919; https://doi.org/10.3390/jpm12111919
Submission received: 23 October 2022 / Revised: 10 November 2022 / Accepted: 15 November 2022 / Published: 17 November 2022
(This article belongs to the Special Issue Personalized and Precision Medicine 2022)

Abstract

Cancer hallmark genes and proteins orchestrate and drive carcinogenesis to a large extent, therefore, it is important to study these features in different cancer types to understand the process of tumorigenesis and discover measurable indicators. We performed a pan-cancer analysis to map differentially interacting hallmarks of cancer proteins (DIHCP). The TCGA transcriptome data associated with 12 common cancers were analyzed and the differential interactome algorithm was applied to determine DIHCPs and DIHCP-centric modules (i.e., DIHCPs and their interacting partners) that exhibit significant changes in their interaction patterns between the tumor and control phenotypes. The diagnostic and prognostic capabilities of the identified modules were assessed to determine the ability of the modules to function as system biomarkers. In addition, the druggability of the prognostic and diagnostic DIHCPs was investigated. As a result, we found a total of 30 DIHCP-centric modules that showed high diagnostic or prognostic performance in any of the 12 cancer types. Furthermore, from the 16 DIHCP-centric modules examined, 29% of these were druggable. Our study presents candidate systems’ biomarkers that may be valuable for understanding the process of tumorigenesis and improving personalized treatment strategies for various cancers, with a focus on their ten hallmark characteristics.
Keywords: hallmarks of cancer; differential interactome; system biomarkers; druggability; personalized treatments hallmarks of cancer; differential interactome; system biomarkers; druggability; personalized treatments

Share and Cite

MDPI and ACS Style

Kori, M.; Ozdemir, G.E.; Arga, K.Y.; Sinha, R. A Pan-Cancer Atlas of Differentially Interacting Hallmarks of Cancer Proteins. J. Pers. Med. 2022, 12, 1919. https://doi.org/10.3390/jpm12111919

AMA Style

Kori M, Ozdemir GE, Arga KY, Sinha R. A Pan-Cancer Atlas of Differentially Interacting Hallmarks of Cancer Proteins. Journal of Personalized Medicine. 2022; 12(11):1919. https://doi.org/10.3390/jpm12111919

Chicago/Turabian Style

Kori, Medi, Gullu Elif Ozdemir, Kazim Yalcin Arga, and Raghu Sinha. 2022. "A Pan-Cancer Atlas of Differentially Interacting Hallmarks of Cancer Proteins" Journal of Personalized Medicine 12, no. 11: 1919. https://doi.org/10.3390/jpm12111919

APA Style

Kori, M., Ozdemir, G. E., Arga, K. Y., & Sinha, R. (2022). A Pan-Cancer Atlas of Differentially Interacting Hallmarks of Cancer Proteins. Journal of Personalized Medicine, 12(11), 1919. https://doi.org/10.3390/jpm12111919

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop